In 2014 managed entry agreements (MEA) between Swedish health care payers (regions), the reimbursement authority (the Dental and Pharmaceutical Benefits Agency (TLV)) and pharmaceutical companies were introduced to facilitate early and equal access to treatments. MEAs complement the value-based pricing system for out-patient drugs and enables stakeholders to negotiate risk-sharing agreements to manage uncertainties at launch.